Hospital La Luz Grupo Quironsalud
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Hospital La Luz Grupo Quironsalud is conducting a series of studies focused on major cardiovascular conditions such as atherosclerotic cardiovascular disease, atrial fibrillation, and various forms of heart failure (preserved and mildly reduced ejection fraction). These trials aim to evaluate new therapies that can lower the risk of heart attacks, strokes, and cardiovascular death, while also improving overall survival and reducing hospitalizations.
- Risk reduction strategies for atrial fibrillation patients
- LDL‑C lowering with novel agents
- Anti‑inflammatory treatments for heart failure with preserved ejection fraction
- Therapeutic approaches for cardiac AL amyloidosis
- Prevention of coronary heart disease major adverse events
With nine investigators leading nine active trials, the cardiology department at this Madrid‑based site is at the forefront of advancing cardiovascular care in Europe.
Eye Diseases
Research at the center includes a study on geographic atrophy secondary to age‑related macular degeneration, exploring how systemic inhibition of Complement Component 5 (C5) can slow lesion growth. The goal is to improve long‑term visual outcomes for patients with progressive retinal loss.
- Complement inhibition to limit geographic atrophy progression
- Combination therapy with subcutaneous pozelimab and cemdisiran
- Assessment of safety and efficacy in retinal disease
These eye‑focused trials complement the site’s broader therapeutic portfolio, offering hope for innovative treatments in ophthalmology.
Immune System Diseases
The cardiology unit also investigates disorders of the immune system, notably AL amyloidosis linked to plasma cell dyscrasia. Studies evaluate the addition of CAEL‑101 to standard plasma cell therapy to improve survival and reduce cardiovascular hospitalizations, while monitoring safety and tolerability.
- Combination therapy for cardiac AL amyloidosis
- Systemic complement inhibition as an immune‑modulating strategy
- Targeting inflammation in heart failure patients
By bridging cardiology and immunology, the site advances multidisciplinary approaches to complex diseases.
Other Research Areas
In addition to cardiovascular and ocular studies, the institution runs a trial addressing acute severe postoperative pain. The research compares an intravenous ibuprofen‑tramadol combination with standard analgesic regimens to determine whether it provides comparable or superior pain relief.
- Evaluation of IV ibuprofen‑tramadol for postoperative pain
- Comparison with conventional tramadol therapy
- Safety and efficacy assessment in acute pain management
This pain‑management study highlights the site’s commitment to improving patient care across diverse clinical settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital La Luz Grupo Quironsalud
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.